Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | GNRHR | P30968 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2241024 | 0.85 | CA1 (0.48) | GAACA1CA2SIGMAR1CYP3A4 | |
| SCHEMBL24350075 | 0.83 | NPC1 (0.54) | POLBGAACA1CA2 | |
| SCHEMBL17410238 | 0.78 | CA1 (0.48) | CA1CA2CYP3A4IDO1BRD4 | |
| SCHEMBL753332 | 0.78 | GAA (0.49) | POLBGAACA1CA2SIGMAR1 | |
| SCHEMBL6239081 | 0.78 | CTSS (0.44) | GAACA1CA2CTSSCTSK | |
| SCHEMBL1929771 | 0.78 | SIGMAR1 (0.52) | GAACA1CA2SIGMAR1CYP3A4 | |
| SCHEMBL3569604 | 0.78 | MAPT (0.48) | POLBGAACA1CA2 | |
| SCHEMBL24310073 | 0.77 | PTPN1 (0.55) | SIGMAR1 | |
| SCHEMBL3571655 | 0.77 | CA1 (0.47) | GAACA1CA2SIGMAR1CYP3A4 | |
| SCHEMBL14366353 | 0.76 | MAPT (0.48) | POLBCA1CA2CYP3A4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2266958-B1 | Antiviral agent | SHIONOGI & CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| US-20170066754-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9572813-B2 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20150202208-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2015-07-23 | — | — | US | disclosed |
| CN-101513402-B | Antiviral agent | SHIONOGI & CO | 2012-03-21 | — | — | CN | disclosed |
| EP-2181985-B1 | Antiviral Agent | SHIONOGI & CO (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20040229909-A1 | Antiviral agent | SHIONOGI & CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| EP-1422218-A1 | ANTIVIRAL AGENT | SHIONOGI & CO., LTD. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229909-A1 | Antiviral agent | ZC3HAV1, ZC3HAV1L, DUT | POLB 89/4885GAA 1106/4885CA1 4794/4885 |
| US-20150202208-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | POLB 107/4885GAA 1442/4885CA1 4422/4885 |
| US-20170066754-A1 | ANTIVIRAL AGENT | ZC3HAV1, ZC3HAV1L, CCNI | POLB 107/4885GAA 1442/4885CA1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.